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We performed a double-blind placebo-controlled trial to
study whether early treatment with erythropoietin could
prevent the development of acute kidney injury in patients in
two general intensive care units. As a guide for choosing the
patients for treatment we measured urinary levels of two
biomarkers, the proximal tubular brush border enzymes
c-glutamyl transpeptidase and alkaline phosphatase.
Randomization to either placebo or two doses of
erythropoietin was triggered by an increase in the biomarker
concentration product to levels above 46.3, with a primary
outcome of relative average plasma creatinine increase from
baseline over 4 to 7 days. Of 529 patients, 162 were
randomized within an average of 3.5 h of a positive sample.
There was no difference in the incidence of erythropoietin-
specific adverse events or in the primary outcome between
the placebo and treatment groups. The triggering biomarker
concentration product selected patients with more severe
illness and at greater risk of acute kidney injury, dialysis, or
death; however, the marker elevations were transient. Early
intervention with high-dose erythropoietin was safe but did
not alter the outcome. Although these two urine biomarkers
facilitated our early intervention, their transient increase
compromised effective triaging. Further, our study showed
that a composite of these two biomarkers was insufficient for
risk stratification in a patient population with a
heterogeneous onset of injury.
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Acute kidney injury (AKI), is a major complication of
patients admitted to the intensive care unit (ICU), with a
mortality of 30–80%.1 There have been no successful
intervention trials after diagnosis of AKI.2 Failure to replicate
the successful experimental treatment of AKI has been
attributed to the 48- to 72-h delay in diagnosis from using
plasma creatinine (pCr) and the underlying heterogeneity of
the etiology, duration, severity, and comorbidity among
patients.2
Patient heterogeneity has been approached by consensus
re-definition of AKI, grading of severity based on defined
increases in pCr, reduction in glomerular filtration rate and
urine output.3,4 Population studies have shown that these
new definitions predict further decline in renal function5 and
mortality.6,7 Nevertheless, problems with reliability of
creatinine in AKI, and absence of real-time measurement
of glomerular filtration rate, have stimulated a search for
alternative injury biomarkers.8–11 Urinary biomarkers with an
area under the receiver-operator-characteristic curve (AUC)
value 40.9 that find use in prediction of the development
of AKI include g-glutamyltranspeptidase (GGT) alkaline
phosphatase (AP), kidney injury molecule-1, interleukin-18,
liver fatty acid-binding-protein, and neutrophil–gelatinase-
associated lipocalin.12–16 None have been used to screen patients
for treatment.
Whereas experimental treatments for AKI show promise,17
erythropoietin is an experimentally validated renoprotective
agent with an established safety profile in treating ane-
mia.18–21 Increased excretion of GGT and AP, two typical
enzymes found in proximal tubules, implies injury to the
brush border of the proximal tubules, a feature of early
ischemic injury.22–25 At the time this study was commenced
these urinary enzymes were the only confirmed12 and rapidly
measurable renal injury biomarkers available.
EARLYARF was both a randomized, placebo-controlled,
double-blind trial of the role of erythropoietin-b to
ameliorate or prevent the development of AKI in ICU
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patients, and a novel proof-of-concept study of the
prospective use of GGTAP to triage patients to early
treatment of AKI.
RESULTS
Between 5 March 2006 and 8 July 2008, 3966 patients were
screened and 499 general ICU and 30 cardiothoracic surgery
patients were enrolled (Figure 1). Of 184 patients with an
elevated GGTAP index (EA2 cohort), 163 were rando-
mized to placebo (78) or erythropoietin (84) and started
treatment (note, 1 patient withdrew consent for recording
data). Most patients were randomized after the first sample
(103). The intervention trial cohort comprised the remaining
162 randomized patients. Patient exclusions are summarized
in Figure 1. The triage trial comprised all patients.
The baseline characteristics are shown in Table 1 for all
patients and in Table 2 for randomized patients. More
patients in the placebo group (n¼ 31, 40%) had AKI on
randomization as compared with that in the EPO group
(n¼ 23, 27%), according to the Acute Kidney Injury Network
(AKIN) creatinine changes criteria (not significant; Table 2).
The EPO group patients were older (P¼ 0.011); less likely to
3966 Patients screened
Exclusion criteria
1. Under 16 years of age
2. Without an indwelling urinary catheter
3. Had obvious hematuria, rhabdomyolysis and/or myoglobinuria, or polycythemia
    (Hb>165 g/l or Hct >48 in women and Hb>185 g/l or Hct >52 in men)
5. Expected to leave within 24 h
6. Not expected to survive 72 h
7. Had aready experienced a greater than three-fold rise in plasma creatinine from
    a known baseline or had a urine output less than 0.3 ml/kg/h for >6 h (anuric)
8. No consent
529 Enrolled
Yes No
during
7 days
No
after
7 days 345 Observation arm
(EA1)
GGTxAP index
≥46.3
184 Treatment arm
(EA2)
163 Randomized
(ITT)
21 Not randomized
1 Consent withdrawn (information not recorded)
84 Erythropoietin
15 Sampling for < 96 h 14 Sampling for < 96 h
4    Died before 2nd dose 1    Died before 2nd dose
3    Died before 96 h 4    Died before 96 h
1    Medically excluded 2    Medically excluded
1    Withdrew consent
3    Received doses not within
      the prescribed time period
1    Received dose not within
      the prescribed time period
1    Received only 1 dose
2    Received doses from non-
      matching study kits
1    Rhabdomyolysis
2    Incorrect dose volume
1    Anuria
1    Rhabdomyolysis
1    Incorrect dose volume
78 Placebo
63 Placebo
(PP)
70 Erythropoietin
(PP)
11  Unable to receive study drug within 6 h
7    Excluded for medical reasons 
2    Withdrew consent
1    Died
3437 Excluded
4. Receiving cytotoxic chemotherapy or renal replacement therapy (RRT), or
    assessed to need RRT within 48 h
Figure 1 | Study protocol and patient flow.
Table 1 | Cohort characteristics on entry to ICU
EA1
(GGTAP
p46.3)
(n=345)
EA2
(GGTAP
446.3)
(n=183)b
Age (yrs) 60±18 61±16
Sex (% Female) 36.8 45.4
Weight (kg) 81±20 77±19d
APACHE II score 17±6 19±7e
SOFA score 6.1±2.7 6.6±2.9
Time to first sample after entry to ICU (h) 3.5±5.4 3.0±4.3
Baseline plasma creatininea (mg/dl) 0.91
(0.72–1.11)
0.79 (0.68–0.97)f
Baselinea eGFR (ml/min) 89 ± 36 96±33d
Length of ICU stay (h) 145±209 169±210
%FENa o1% (n) 80.1 (270) 74.6 (135)
%FENa 1–2% (n) 13.4 (45) 10.5 (19)
%FENa 42% (n) 6.5 (22) 14.9 (27)f
Plasma creatinine (mg/dl) 1.0 (0.79–1.4) 1.0 (0.79–1.3)
Plasma cystatin-C (mg/l) 0.87
(0.65–1.24)
0.90 (0.73–1.24)
4 h Creatinine clearance (ml/min) 83 (50–128) 66 (43–104)e
AKI (%, AKIN) 26.7 (90) 30.1 (55)
BUN (mg/dl) 18 (12–28) 19 (13–26)
eGFR (ml/min) 73 (47–96) 73 (52–98)
Hematocrit 0.35
(0.30–0.39)
0.33 (0.29–0.38)
Hemoglobin 115 (100–131) 109 (95–126)
Lowest daily MAP 60±12 60±12
Highest daily MAP 96±17 98±19
24 h Urine output (ml) 2080±1330 1860±1240
GGTAP 10±11 6.1
(2.3–14)
466±2390g 678
(21–169)g
Principal diagnostic group % (n)
Abdominal aortic aneurysm
rupture and repair
2.0 (7) 9.2 (17)
Abdominal surgery or inflammation 7.5 (26) 15.2 (28)
Burns 1.4 (5) 0
Cardiac arrest or failure 8.1 (28) 19.0 (35)
Cardiac surgeryc 19.7 (68) 14.1 (26)
Collapse, cause unknown 0.9 (3) 0
Neurological surgery, injury or
seizure or intracranial hemorrhage
17.7 (61) 7.1 (13)
Pulmonary or thoracic surgery
or failure
13.0 (45) 10.3 (19)
Sepsis 19.1 (66) 19.0 (35)
Trauma 9.9 (34) 4.9 (9)
Other 0.6 (2) 0.5 (1)
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network;
AP, alkaline phosphatase; BUN, blood urea nitrogen; eGFR, estimated glomerular
filtration rate; FENa, fractional sodium excretion; GGT, g-glutamyltranspeptidase;
ICU, intensive care unit; MAP, mean arterial pressure.
Results are mean±standard deviation or median (interquartile range).
aBaseline plasma creatinine and eGFR determined retrospectively as described in the text.
There were no differences in the proportion of patients whose baselines was allocated by
each of the various methods used to determine baselines between EA1 and EA2.
bEA2 patient data are pre-randomization; n was reduced to 162 after randomization.
cIncludes the 30 CTS patients recruited before surgery (EA1, n=21; EA2, n=9).
Significance of EA1 versus EA2: d: Po0.05; e: Po0.005; f: Po0.001; g: Po0.0001.
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have had neurological surgery, injury or seizure or intracra-
nial hemorrhage (Po0.05); and more likely to have had
sepsis (Po0.05; Table 2).
Intervention efficacy
There was no significant difference in the primary outcome
between the groups for either the Intention-To-Treat (ITT) or
Per-Protocol (PP) cohort (Table 3), and no significant differ-
ence after correction for age, neurological surgery, injury or
seizure or intracranial hemorrhage, and sepsis (P¼ 0.58).
There was no significant difference in secondary outcomes
with the exception of the incidence of AKI (at or within
approximately 48 h of randomization) on the basis of the
urine output criteria alone (AKI AKIN-UO, 50.8 versus
70%), with lower incidence in the placebo group (Table 3).
These analyses were not different for the PP cohort (data not
shown). None of the creatinine-based variables showed any
significant difference between the groups, and pCr relative to
baseline decreased with time from randomization for both
the groups (Figure 2). In the subgroup of randomized
patients who did not have AKI on randomization (n¼ 104),
the Relative Average Value of Creatinine (RAVC) was
significantly higher in the EPO group (8.5±27 (n¼ 61)
compared with 4.6±18 (n¼ 47) for the placebo group,
P¼ 0.004) as was AKI AKIN-UO (see Appendix). There were
Table 2 | ITT cohort characteristics
Randomized (ITT)
Placebo
(n=78)
EPO
(n=84)
On entry to ICU
Age (years) 58±17 65±14d
Sex (% female) 42.3 45.2
Weight (kg) 76±18 78±20
APACHE II Score 19±7 20±6
SOFA score 6.5±2.9 6.7±3.0
Time to first sample after entry to ICU (h) 2.2±2.9 3.3±5.0
Baseline plasma creatininea (mg/dl) 0.79
(0.68–0.93)
0.79
(0.68–1.02)
Baselinea eGFR (ml/min) 96 (75–114) 91 (70–115)
Length of ICU stay (h) 84 (42–180) 86 (45–163)
%FENa o1% (n) 76.9 (n=60) 70.7 (n=58)
%FENa 1–2% (n) 7.7 (n=6) 12.2 (n=10)
%FENa 42% (n) 15.4 (n=12) 17.1 (n=14)
On randomization
Plasma creatinine (mg/dl) 1.02
(0.78–1.36)
1.02
(0.70–1.33)
Plasma cystatin-C (mg/l) 0.92
(0.67–1.31)
1.02
(0.80–1.38)
4 h creatinine clearance (ml/min) 83 (50–104)
(n=73)
65 (39–96)
(n=74)
AKI % (n) (AKIN) 40 (31) 27 (23)
BUN (mg/dl) 17.2 (12.7–26) 19.9
(14.6–24.5)
eGFR (ml/min) 72 (52–99) 70 (51–104)
Hematocrit 0.33
(0.27–0.39)
0.33
(0.28–0.38)
Hemoglobin 111 (90–131) 104 (93–125)
Lowest daily MAP 66±12 63±13
Highest daily MAP 98±20 96±18
24 h urine output (ml) 2020±1150 1820±1120
GGTAP 741±3570 274±473
105 (66–242) 82 (62–227)
Randomization time (h)b 3.4±1.5 3.6±1.5
Randomized on first sample % (n) 65.4 (51) 61.9 (52)
Principal diagnostic group % (n)
Abdominal aortic aneurysm rupture
and repair
10.3 (8) 9.5 (8)
Abdominal surgery or inflammation 11.5 (9) 17.9 (15)
Burns 0 0
Cardiac arrest or failure 20.5 (16) 20.2 (17)
Cardiac surgeryc 15.4 (12) 14.3 (12)
Collapse, cause unknown 0 0
Neurological surgery, injury, or seizure
or intracranial hemorrhage
12.8 (10) 3.6d (3)
Pulmonary or thoracic surgery or
failure
10.3 (8) 7.1 (6)
Sepsis 11.5 (9) 23.8d (20)
Trauma 6.4 (5) 3.6 (3)
Other 1.3 (1) 0
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AP, alkaline
phosphatase; eGFR, estimated glomerular filtration rate; EPO, erythropoietin-b; GGT,
g-glutamyltranspeptidase; ICU, intensive care unit; ITT, Intention-To-Treat; MAP, mean
arterial pressure.
Results are mean±s.d., median (interquartile range), or % (n).
aBaseline plasma creatinine and eGFR determined retrospectively as described in the
text. There were no differences between EA1 and EA2 in the proportion of patients
whose baselines were allocated by each of the various methods used to determine
baselines.
bAfter sampling for elevated GGTAP (not necessarily the initial sample on ICU
admission).
cIncludes the 30 CTS patients recruited before surgery (placebo, n=4; EPO, n=4).
dSignificance of EPO versus placebo: Po0.05.
Table 3 | Intervention trial efficacy of erythropoietin
Placebo EPO P
(a) Continuous (non-categorical) variables
Primary outcome
ITT population (n=78) (n=84)
RAVC 17±44 23±49 0.40
9.0 (9.4–33.6) 10.7 (1.8–32.2) 0.36
PP population (n=63) (n=70)
RAVC 12±38 22±46 0.20
8.2 (11–30) 11 (1.9–29) 0.20
Secondary outcomes (n=78) (n=84)
Length of ICU Stay (h) 84 (43–80) 86 (45–163) 0.91
Length of hospital stay
(days)
27 (14–48) 22 (14–45) 0.69
(b) Categorical
variables % (n)
AKI in 7days 48.7 (38) 48.8 (41) 1.0
AKI AKIN-creatininea 47.4 (37) 45.2 (38) 0.88
AKI AKIN-UOa 51.3 (40) 70.2 (59) 0.016
AKI AKIN-Totalb 69.2 (54) 78.6 (66) 0.21
AKI RIFLE-creatininec 19.2 (15) 23.8 (20) 0.57
Dialysis in 30 days 3.8 (3) 6.0 (5) 0.72
Death in 7 days 16.7 (13) 10.7 (9) 0.36
Death in 30 days 21.8 (17) 19.0 (16) 0.70
Abbreviations: AKI, acute kidney injury; AKIN, acute kidney injury network; EPO,
erythropoietin-b; ICU, intensive care unit; PP, Per-Protocol; RAVC, Relative Average
Value of Creatinine; UO, urine output.
Results are mean±s.d., median (interquartile range), or % (n).
aAKIN-creatinine and percentage increase definitions include the first plasma
creatinine measurement beyond 48 h (mean 57±13 h).
bAKI AKIN-Total: The sum of AKI AKIN-creatinine, AKI AKIN-UO, and dialysis in 7 days.
AKI in 7 days: At least a 50% rise or a 0.3-mg/dl (26.4-mmol/l) rise from baseline or
dialysis within 7 days of randomization.
cAKI RIFLE-creatinine: At least a 50% rise from baseline sustained for at least 24 h
within 7 days of randomization.
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no differences in the length of ICU or hospital stay, need for
dialysis, or mortality.
Survival curve analysis for survival and need for dialysis
showed that there was no significant difference regarding 180
days between EPO and placebo (hazard ratio for survival:
0.95 (95% confidence interval (CI) 0.52–1.7), log rank test
P¼ 0.85); hazard ratio for dialysis: (0.98 (95% CI 0.53–1.8),
log rank test P¼ 0.94).
There were no significant differences between the EPO and
placebo groups regarding incidence of grade-3 or higher
adverse events (AEs) except for a larger number of acidosis
and alkalosis episodes in EPO-treated patients (Po0.003)
(see Appendix). As there was no time-based association and
as both acidosis and alkalosis were more frequent in the EPO
group, these events appear of doubtful clinical significance.
There was no difference in the incidence of EPO-specific AEs
in the placebo and EPO groups.
Triage efficacy
Randomization occurred 3.5±1.6 h after procurement of
urine sample with an increased GGTAP index with 97.5%
under the 6-h goal, Table 1. Most patients were randomized
after the first sample (64%, n¼ 105). This was achieved in
6.3±4.2 h after admission to ICU. An increased GGTAP
index selected patients (EA2) with higher APACHE II score,
more likely to have an fractional sodium excretion42% and
lower creatinine clearance on admission (Table 1). The EA2
cohort was more likely than EA1 to experience a negative
outcome in the first week (AKI according to RIFLE, dialysis,
or death; Table 4; P¼ 0.0006) with a relative risk of 1.5 (CI
1.2–1.9). Each of RIFLE, dialysis, and death were individually
significant (Po0.05). The EA2 cohort also had a higher
RAVC from admission and longer hospital stay in the ICU.
The predictive value of GGTAP on admission for AKI
was poor and for renal replacement therapy and death it was
low (Table 5). Without the potential confounding of AKI on
entry, the AUCs improved with GGTAP becoming mode-
rately predictive for renal replacement therapy (AUC¼ 0.69).
Three typical situations where GGTAP identified cases
of AKI in advance of change in pCr are illustrated in Figure
3a and c, and contrasted with three cases where GGTAP
failed to diagnose AKI that subsequently developed (Figure
3b and d).
GGTAP peaked at approximately 6 h after insult
(Figure 4a) and had a median (interquartile range) duration
of 12.3 (11.3–26.3) hours, which was above the threshold for
all EA2 patients. Heterogeneity in time from insult to first
sample reduced the triage efficacy by reducing the discrimi-
natory ability of the first sample (see Figures 4b and c).
Subdividing patients into three groups according to time
from insult (o6 h, 6 to 12 h, and 412 h) showed that the
maximum AUC for AKI was 6 to 12 h after putative insult
(AUC¼ 0.69 (CI 0.55–0.84); Figure 4d). Similarly the
predictive AUCs for dialysis and death were higher in the
6- to 12-h subgroup (Table 5).
DISCUSSION
This is the first randomized, placebo-controlled, double-
blind trial of intervention in AKI with EPO. This trial allowed
an assessment of the safety of high-dose EPO and provided
insight into its potential benefit. As experimental studies had
shown renoprotection by EPO up to 6 h after reperfusion
following ischemia,21 we aimed to randomize patients within
6 h of detection of kidney injury after entry into ICU.
There was no biologically significant renoprotection or
amelioration of AKI after EPO. There was an imbalance in
age and sepsis and neurological events between the EPO and
placebo groups, which occurred by chance. However,
correction for these made no difference to the outcome. A
subgroup analysis of patients without AKI on randomization
suggested that EPO may negatively affect renal function,
resulting in a higher RAVC. As the study was not powered for
such a subgroup analysis, this result must be viewed with
caution. EPO was not associated with increase in clinically
significant serious AEs. In particular, there was no evidence
for increased intravascular thrombosis or sequelae thereof.
This is relevant to 24 other currently registered clinical trials
using EPO (International trial registry data http://
www.who.int/trialsearch; accessed 16 March 2009). It sup-
ports the absence of harm reported in the pilot stroke
neuroprotection study.26 This contrasts with a significantly
higher mortality in the EPO arm in a more adequately
powered, completed stroke study.27 As in the EARLYARF
trial, both stroke studies used similar high doses of EPO
(100 000 U over 3 days), but the lower than expected
mortality in the placebo arm of the Ehrenreich study suggests
this outcome must also be viewed with caution.
This is the first early intervention (also known as
secondary prevention28) study to test the concept that a
urinary biomarker can triage patients at high risk of AKI to
early treatment.28 The product of GGT and AP was selected
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Figure 2 |Change in plasma creatinine after intervention with
EPO (closed circles) or placebo (open circles) in patients
triaged using an increased urinary GGTAP index. The error
bars indicate the standard errors of the mean.
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Table 4 | Triage trial efficacy of GGTAP: comparison of outcomes
EA1 (n=345) EA2 (n=183) P
ICU length of stay (h) 69 (42–162) 91 (46–190) 0.070
RAVC from admission 14±38 25±51 0.0094
7.0 (7.0 to 21.6) 10.7 (3.4 to 34.8) 0.056
Outcomes within 7 days of entry (EA1) or raised GGTAP (EA2), % (n)
AKI RIFLE-creatinine 15.1 (52) 23.0 (42) 0.031
Dialysis 2.3 (8) 6.0 (11) 0.047
Death 8.1 (28) 14.2 (26) 0.034
AKI RIFLE-creatinine or dialysis or death 21.4 (74) 35.5 (65) 0.0006
Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; RAVC, relative average value of creatinine.
Results are mean±s.d., median (inter-quartile range), or % (n).
AKI RIFLE-creatinine: At least a 50% increase from baseline sustained for at least 24 h within 7 days of ICU entry.
Table 5 | Triage trial efficacy of GGTAP on admission to ICU: comparison of all patients with those without AKI on admission
and those 6–12h from insult
AUC (95% CI) All patients
Not AKI (AKIN) on
admission
(n=383)
Between 6 to 12 hours of
insult and not AKI on admission (n=103)
AKI AKIN-creatinine 0.55 (0.50 to 0.60) 0.57 (0.50 to 0.64) 0.69 (0.55 to 0.82)
AKI RIFLE-creatinine 0.55 (0.49 to 0.62) 0.63 (0.52 to 0.75) 0.68 (0.45 to 0.90)
Dialysis 0.62 (0.48 to 0.76) 0.69 (0.53 to 0.86) 0.75 (0.52 to 0.98)
Death in 7 days 0.63 (0.55 to 0.72) 0.66 (0.55 to 0.76) 0.73 (0.48 to 0.99)
Death in 30 days 0.59 (0.52 to 0.66) 0.62 (0.54 to 0.71) 0.71 (0.50 to 0.92)
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; AUC, area under the receiver-operator-characteristic curve; CI, confidence interval; ICU, intensive
care unit.
AKI AKIN-creatinine: At least a 50% or 0.3mg/dl increase from baseline sustained by the 1st sample following 48 hours ICU entry.
AKI RIFLE-creatinine: At least a 50% increase from baseline sustained for at least 24 h within 7 days of ICU entry.
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Figure 3 |Case studies. Examples of true positives (a, c) and false negatives (b), and (d) for AKI (AKIN definition) defined by triaging with
GGTAP. Key: True Positives: (i) ID032: 85-year-old female with respiratory failure, received placebo, AKI by 24 h, died on day 6; (ii) ID095: 67-
year-old female with cardiac arrest, received EPO, AKI by 12 h, survived; (iii) ID151: 71-year-old male, ruptured abdominal aortic aneurysm,
received EPO, AKI by 12 h, survived. False negatives: (i) ID061: 72-year-old female with respiratory failure, AKI by day 3, died on day 3;
(ii) ID087; 72-year-old female with sepsis, AKI by day 2, survived; (iii) ID187: 24-year-old female following neurosurgery, AKI by 24 h, survived.
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as it had been shown to be highly predictive of AKI
(AUC¼ 0.94 (CI: 0.73–0.99)) in a small pilot study and
confirmed as sensitive (100%) and specific (91%) in an
additional cohort at a cut-off of 46.3.12 GGT and AP were the
only rapidly measurable renal injury biomarkers available at
the time this project was commenced. The cut-off of 46.3 was
selected to include all possible cases of AKI and therefore
expected to include some false positives. The widespread
availability of GGT and AP assays also suggested easy clinical
translational benefit should utility be confirmed.
A GGTAP value greater 46.3 selected a high-risk group
with more severe illness and at greater risk of AKI, dialysis, or
death, and with an elevated level of renal injury biomarker
out of a general ICU population. Almost all patients were
randomized within 6 h. However, although moderately
predictive of dialysis, the overall utility of GGTAP as a
triaging tool was limited. On admission to ICU, the incidence
of AKI (AKIN definition) in the observation arm and the
intervention arms was similar (26.7 versus 30.1%, P¼ 0.42;
Table 1). Whereas subsequent incidence in the observation
arm was lower (18.6 versus 27.3%, P¼ 0.06), the high overall
incidence of AKI in the observation arm represents a high
false negative rate for prediction of AKI by GGTAP. This
suggests that the time course of GGTAP elevation was brief
enough to lower the GGTAP below the threshold before
ICU entry, or that the threshold was inappropriately high.
Both individual cases (Figure 3c and d) and re-plotting the
GGTAP profiles against the time from insult instead of the
time after ICU admission (Figure 4b and c) support the
suggestion that the brief time course was responsible for the
high false negative rate. Given the short detection window,
the delay produced by screening only on entry to ICU (rather
than earlier) appears to have been responsible for the high
false negative rate.
Biomarker performance in more heterogeneous (ie, less
selected) groups, with variable severity and variable sampling
relative to injury time, may be a reason why follow-up
biomarkers studies often report lower predictive values than
highly discriminatory initial reports.8 Nevertheless, the
predictive value of GGTAP for AKI in patients without
AKI on admission was low. This was not an artifact of
definitions of baseline or AKI different from those in the pilot
study as the AUC for AKI using definitions identical to those
in the pilot study was still poor (0.65 (CI 0.55–0.75)). If
patients were grouped according to the time following renal
insult, then Figure 4d (and Table 5) shows that the predictive
value of GGTAP in patients without AKI on admission
increases up to 12 h after which it becomes non-predictive.
These changes mimic the profile of GGTAP changes after
cardiopulmonary bypass surgery (CPB) (Figure 4) and
highlight the likely ‘window of opportunity’ during which
this particular biomarker could be used for triaging. Other
potential biomarkers will also have a window, which may
explain some of the variations in the prognostic performance
of other biomarkers at a single time point.28
The timing of screening at ICU admission, and imperfect
triaging into the intervention arm, limits the conclusions that
can be drawn regarding the efficacy of early intervention with
EPO. The intervention trial became, in effect, an EPO trial of
critically ill patients, with a typical overall incidence of AKI of
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Figure 4 |Urinary GGTAP index (mean±s.e.m.) in patients who did not receive EPO and who either developed (closed circles) or
did not develop AKI (AKIN definition, open circles). Time courses are shown for (a) cardiopulmonary bypass (CPB) patients (n¼ 93) timed
from the start of CPB (on-pump; time 0 measurements taken pre-operatively); (b) all patients, including cardiothoracic surgery patients,
timed from enrolment at ICU entry; and (c) as for panel b, but timed from a post hoc estimate of time of renal insult. Panel d shows the
predictive area under the curve (AUC ±95% CI) of the GGTAP ROC curve for developing AKI for three groups of patients grouped
according to time from insult who were not AKI on entry. n¼ number in each group (number of AKI).
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33%. Although the time to randomization of those
randomized after the first sample, 6.3±4.2 h, was brief as
compared with that in other intervention trials (e.g.
references Allgren et al.29 and Hirschberg et al.30), but at a
median of 12.9 (9.6–26.8) hours following renal insult in the
majority of patients, it was still more than 6 h, the upper limit
suggested in experimental AKI.21
Thus the potential therapeutic renoprotective benefit of EPO
is not excluded by this study. As a snapshot of a realistic general
ICU population, this study highlights the need to understand
the individual time course of each injury biomarker and
supports simultaneous use of multiple biomarkers with
different profiles to identify the stage of injury.8,31,32
An increased GGTAP index on admission to ICU was
modestly predictive of renal replacement therapy and slightly
less predictive of death within 7 or 30 days. Apart from
association with AKI, a reason for this association with
increased early mortality is unknown. An association of plasma
GGT with cardiovascular and all-cause mortality in chronic
kidney disease was recently attributed to oxidative stress.33
Since the inception of this trial other biomarkers have
shown promise as potential triaging tools and even point-of-
care testing is being developed (e.g., for plasma neutrophil–-
gelatinase-associated lipocalin and urinary kidney injury
molecule-134). Retrospective testing has shown that urinary
neutrophil–gelatinase-associated lipocalin, kidney injury mo-
lecule-1, interleukin-18, and liver fatty acid-binding-protein
are highly predictive of AKI after cardiac surgery.14,15,35,36
Urinary neutrophil–gelatinase-associated lipocalin and inter-
leukin-18 have also been shown to be predictive of AKI in the
emergency department and the ICU, respectively.13,37
The study uncovered other limitations relevant to future
biomarker-based trials. As diagnosis of reversible pre-renal
AKI is retrospective,37 such patients could not be excluded
by early triaging on the basis of a biomarker of injury alone.
A low fractional sodium excretion in the majority of random-
ized patients suggests that renal sodium reabsorption was
preserved despite biomarker evidence of injury. While this
highlights our lack of understanding of what pre-renal AKI
actually means (see reference Bellomo et al.38), if such patients
were volume-responsive, this would reduce the power of the
study with respect to EPO efficacy.
Second, the appropriate endpoint in AKI intervention
trials is controversial.39–42 Surrogate endpoints are appro-
priate for early intervention studies. Categorical variables,
such as AKIN or RIFLE stages, depend on change in pCr and
are therefore secondary to changes in filtration function, and
not directly related to structural injury. Nevertheless, they
have been associated with increased mortality.5,7,43,44 We
relied on change in pCr as a surrogate endpoint, but used a
continuous variable, RAVC, integrated over a long period of
time (4–7 days), rather than a categorical variable measured
at a single time point. In a simulated trial RAVC has been
shown to more accurately reflect the difference between
treated and placebo groups than categorical metrics, includ-
ing RIFLE and AKIN.45
Third, both categorical and continuous variable defini-
tions of AKI require a reliable estimate of baseline pCr. We
prefer to determine baseline creatinine from measured rather
than estimated variables using prior or post hoc creatinine
measurements with defined rules. This is because using a
formula based on age, gender, and race to estimate a baseline
creatinine overestimates the prevalence of AKI and does not
take into account an individual’s renal function.45,46 The
alternative of using the first creatinine measure in the
ICU does not distinguish between a patient with a high
basal creatinine and one with already established AKI. In
taking the lowest of the on-entry (n¼ 98), final ICU, or
follow-up creatinine (n¼ 142) we attempted to identify
the individual’s normal creatinine (n¼ 20). The distribution
of creatinine levels across each of these methods was
identical. This approach is, of course, only appropriate for
a post hoc analysis. Ideally for an early intervention trial,
patients with AKI on entry should be triaged out. Where a
pre-ICU baseline creatinine is readily available this is
possible; however, when not available, it is not possible to
use a retrospective strategy. One possible solution is to
triage out patients with creatinine above a pre-determined
level (say 1.5 mg/dl) and use the first creatinine measure as
the baseline. An analysis of our primary outcome on the
basis of a baseline of the on-entry creatinine level
showed no significant difference between EPO and placebo
(P¼ 0.07) treatment. The optimal strategy for defining
the baseline and endpoint requires assessment in large
multicenter cohorts.
The progressive decline in pCr in randomized patients
may reflect the current emphasis on volume hydration in
ICU patients,47 and raises the possibility that the majority of
patients had a degree of AKI, making evaluation of baseline
creatinine values more difficult.
Finally, biomarker studies have not shown conclusively
that indexing to urinary creatinine to account for dilution
always improves diagnostic accuracy. Other solutions, such as
calculating the biomarker excretion rate by multiplying
urinary concentration by urine flow rate, need to be explored.
This is the first AKI trial to show the feasibility of rapid
triaging to intervention with a urinary biomarker. Using a
single composite biomarker with a brief post-injury profile
was insufficient for risk stratification in a population with a
heterogeneous onset of injury. A panel of biomarkers with
different time profiles is desirable. The data suggest that brief
exposure to high-dose EPO is safe in this population, but a
larger trial is required to assess efficacy in AKI.
MATERIALS AND METHODS
Study population
Consecutive patients admitted to the general ICU of either
Christchurch or Dunedin Hospital, or high-risk patients scheduled
for cardiothoracic surgery with CPB, were screened for inclusion
(see Figure 1 for exclusion criteria). Cardiothoracic surgery patients
were consented electively if they met the criteria for increased risk of
AKI:48 pCr 41.7 mg/dl or estimated glomerular filtration rate
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25–50 ml/min, and scheduled to undergo CPB for valvular heart
disease or coronary artery bypass grafting plus at least one of the
following: extra-cardiac vascular disease, diabetes mellitus, ejection
fraction o25%, use of a preoperative intra-arterial balloon pump,
emergency surgery, or other surgery.
The study was approved by the multiregional ethics committee of
New Zealand (MEC/050020029) and registered under the Australian
Clinical Trials Registry (ACTRN012606000058572; http://www.
actr.org.au). Screening on entry to ICU was by presumptive consent,
followed by written consent from the patient or family.
Study design
The study comprised an intervention trial and a triage trial running
concurrently. The intervention trial comprised only patients triaged
to intervention (EA2) who were subsequently randomized to
treatment (Figure 1). Patients not triaged to intervention comprised
the observation arm (EA1). The triage trial was to compare all EA2
patients (EPO and placebo) with those in EA1 if there were no
significant differences between treatments; if there were differences
only placebo patients in EA2 would be used.
Intervention trial. The intervention trial was a prospective,
randomized, double-blind, placebo-controlled, parallel-group,
early intervention trial of intravenous EPO to ameliorate the
development of AKI. Eligible patients were allocated to EPO or
placebo (normal saline) groups in a 1:1 ratio, using a predefined
computer-generated randomization sequence with permuted
blocks stratified on center. Concealment was by pharmacist; pairs
of identical 5-ml syringes containing EPO (50 000 U in 3 ml)
or normal saline were prepared and stored. Patients received
an intravenous dose of 500 U/kg to a maximum of 50 000 U, within
6 h of the time of collection the sample with increased GGTAP
and a second dose 24 h later. Weight was known or estimated
from height. Patients, all medical staff, and investigators were
masked to treatment.
The prospectively defined primary outcome was the RAVC,
defined as the average pCr (pC) increase from baseline (pCpCb) as
a percentage of baseline creatinine (pCb).
45 That is
RAVCð%Þ ¼ 100
 
1=t
Z t
0
ðpC  pCbÞdt
!
=pCb
RAVC was calculated using the trapezoidal rule to estimate the
incremental area above baseline from the first value in the ICU (time
0) to the last measure before death or on day 7 (time t).
Triage trial. Patients were triaged to EA2 if GGTAP was
446.3 units (indexed to urinary creatinine; dimensionless); the
threshold was determined from pilot study data to minimize false
negatives (sensitivity was 100% in the pilot study).12 GGTAP was
determined within 1 h of entry to ICU, at 12 h, 24 h, and daily to
7 days. It was hypothesized that early triaging by increased
GGTAP would allow randomization of patients at risk of a
decrease in renal function to occur within 6 h. The outcome
measures were the mean time to randomization following collection
of urine sample with increased GGTAP and identification of
patients most at risk of AKI, dialysis, or death.
Patient monitoring
Spot urine samples for GGT, AP, and creatinine were taken within
1 h of entry to ICU, at 12 h, 24 h, and daily to 7 days for all patients.
Blood for creatinine and cystatin-C, and commencement of 4-h
creatinine clearances were at the same time points. Blood and urine
sodium was measured at 0 and 12 h. EA2 patient sampling
continued for 7 days after increase in GGTAP. Sampling
continued in the wards for patients transferred from the ICU. EA2
patients were followed for serious AEs for 30 days. Urine output was
recorded every 6 h while patients remained catheterized. Renal
function (creatinine) and mortality were monitored in EA2 patients
at 30 and 90 days.
The Data Safety Monitoring Board (DSMB) required AEs with
severity scores 43 to be coded for severity, relatedness, onset,
resolution time, and body system using the Common Terminology
Criteria for Adverse Events (CTCAE) coding system (http://
ctep.cancer.gov/forms/CTCAEv3.pdf). Physiological parameters in-
cluding mean arterial pressure, hemoglobin, and potential EPO-
related AEs (including hypertension, cardiac failure, thromboem-
bolism, myocardial infarction, stroke, seizures, allergic response),
were monitored for 30 days after randomization. Unmasking
followed recording of the final AEs of the patient last enrolled.
Assays
Urine GGT, AP and creatinine, and pCr were assayed immediately.
Creatinine concentrations were determined by the Jaffe Reaction,
and GGT and AP concentrations, respectively, by g-glutamyl-p-
nitroanilide rate and p-nitrophenol rate reactions (IFCC method),
with Abbott agents using an Architect ci8200 analyzer (Christch-
urch) or, with Roche reagents, on a Modular P Analyzer (Dunedin).
There was no significant difference between the means or standard
deviations of the reference samples between the laboratories.
Statistical methods
Intervention trial. The primary outcome and safety endpoints
were evaluated in the ITT population. ITT patients were those with
an increased GGTAP index who had been randomized. As all
randomized patients had received at least one dose of the study
medication; the ITT and safety populations were identical. PP
patients received both doses of study medication, needed at least
96 h for RAVC calculations, and thus, follow-up of at least four post-
randomization pCr samples. Secondary outcomes compared efficacy
using the ITT population.
A baseline creatinine was determined before unmasking using (in
descending order of preference): (1) the most recent pre-ICU value
between 30 and 365 days (n¼ 106), or for elective cardiac surgery
patients, the pre-surgery value (n¼ 33); (2) a stable pre-ICU value
4365 days for patients aged o40 years, (stable defined as within
15% of the lowest ICU measurement) (n¼ 7); (3) pre-ICU 4365
days and less than the initial creatinine on entry to ICU (n¼ 65); (4)
a pre-ICU value (between 3 and 39 days) less than or equal to the
initial on-entry creatinine to ICU and not obviously in AKI
(n¼ 57); (5) the lowest of initial on-entry creatinine to ICU
(n¼ 98), the last ICU value (n¼ 148), or the minimum value at
follow-up to 365 days (n¼ 20) total n¼ 528).
With 65 patients per treatment group, the study was prospec-
tively powered to detect a difference between RAVC means of 5.0%
using unpaired t-test, with 80% power, assuming an s.d. of 0.11 mg/
dl (10 mmol/l), an average baseline pCr of 1.13 mg/dl (100 mmol/l),
and a two-tailed a¼ 0.05. Recruitment continued until there were
130 PP patients. Secondary outcomes, defined before unmasking,
included RIFLE (X50% increase in pCr within 7 days and sustained
for 24 h) and AKIN (X0.3 mg/dl or 50% increase in pCr within
48 h) categorical definitions of AKI, plasma cystatin-C, urine
output, need for dialysis, death within 7, 30 or 90 days.
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Triage trial. Triage efficacy was assessed by the mean time
to randomization after increased GGTAP as compared with the
6-h goal and by the ability of GGTAP to predict outcomes related
to renal function by AUC. These outcomes included categorical
definitions of AKI (as above), need for dialysis, and death within
7 or 30 days. AUCs were also calculated for the subgroup that
did not have AKI (AKIN definition) on admission. Additional
analysis included comparison of the length of hospital stay and
RAVC between EA1 and EA2. Time from insult was defined as the
time period from the estimated time of a possible insult until the
time of the first urine samples. The time of the possible insult was
determined prior to unmasking by chart review (including
ambulance records) where it was assumed all patients had a kidney
insult and that the likely causes were cardiac arrest, time of onset of
CPB, time of onset of anesthetic in other surgeries, time of
documented hypotensive event, time of accident, and time of onset
of illness symptoms.
Categorical outcomes were analyzed using w2 or Fisher’s exact
test and continuous variables were analyzed using independent
t-tests (normally distributed) or Mann–Whitney U-tests (not
normally distributed). The intervention trial was not powered for
survival analysis of dialysis or survival. Nevertheless, we performed
Kaplan–Meier analysis to 180 days and calculated the hazard ratios
for survival and need for dialysis. Statistical analysis was performed
using SPSS 13.0 (SPSS, Chicago, IL, USA), Matlab 2009a (Math-
Works, Natick, MA, USA), and GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA). A two-tailed P-value o0.05 was
taken to indicate statistical significance.
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Appendix
Additional secondary outcomes of the intervention trial are
presented in Table A1. For the subgroup of patients without
AKI on randomization (n¼ 108), Table A2 shows the primary
and main secondary outcomes. Table A3 shows the incidence of
grade-3 or higher AEs in the placebo and EPO groups.
Table A1 | Intervention trial efficacy of erythropoietin: additional secondary outcomes
Placebo
(n¼ 78)
EPO
(n¼ 84) P
(a) Continuous (non-categorical) variables
Peak plasma creatinine (mg/dl) 1.13 (0.79–1.56) 1.14 (0.89–1.61) 0.64
Time to peak plasma creatinine (hours) 44 (22–100) 39 (23–97) 0.90
Absolute increase from baseline to peak plasma creatinine (mg/dl) 0.30 (0.11–0.56) 0.27 (0.11–0.74) 0.50
Relative increase from baseline to peak plasma creatinine (%) 36 (14–71) 40 (17–82) 0.42
Plasma creatinine at 6 or 7 days (mg/dl) [n] 1.0 (0.89–1.22) [69] 1.0 (0.82–13) [76] 0.65
Plasma creatinine at 30 days (mg/dl) [n] 0.85 (0.70–1.11) [57] 0.90 (0.69–1.10) [60] 0.69
Plasma creatinine at 90 days (mg/dl) [n] 0.95 (0.79–1.10) [47] 0.85 (0.74–1.07) [56] 0.41
Length of ICU Stay (h) 84 (43–80) 86 (45–163) 0.91
Length of hospital stay (days) 27 (14–48) 22 (14–45) 0.69
Time to dialysis (h) (n) 53±23 [3] 25±17 [5] 0.088
RAVC maximum value in 7 days 18 (2.7–49) 18 (7–59) 0.44
Cystatin-C
RAVC cystatin-C 5.0 (-8.7–18) 3.6 (-6.5–24) 0.61
RAVC maximum value in 7days 5.8 (4.3 to 21) 9.5 (0.6 to 24) 0.35
Peak cystatin-C (mg/l) 1.1 (0.89–1.6) 1.3 (0.97–1.7) 0.04
Relative increase to peak cystatin-C (%) 33 (13–47) 28 (13–50) 0.93
Time to peak cystatin-C (h) 108 (37–143) 93 (28–141) 0.61
(b) Categorical variables % (n)
Increase of plasma creatinine X0.3mg/dla 47.4 (37) 41.7 (35) 0.53
Increase of plasma creatinine 25%a 56.4 (44) 56.0 (47) 1.0
Increase of plasma creatinine 50%a 35.9 (28) 38.1 (32) 0.87
Increase of plasma creatinine 100%a 14.1 (11) 16.7 (14) 0.67
AKI AKIN-creatininea 47.4 (37) 45.2 (38) 0.88
AKIN stage Ia 33.3 (26) 28.6 (24)
AKIN stage IIa 9.0 (7) 9.5 (8)
AKIN stage IIIa 5.1 (4) 7.1 (6)
AKI AKIN-UOa 51.3 (40) 70.2 (59) 0.016
AKIN I UOa 9.0 (7) 9.5 (8)
AKIN II UOa 32.1 (25) 50.0 (42)
AKIN III UOa 10.3 (8) 10.7 (9)
AKI AKIN-Totalb 69.2 (54) 78.6 (66) 0.21
AKI RIFLE-creatininec 19.2 (15) 23.8 (20) 0.57
RIFLE R 6.4 (5) 13.1 (11)
RIFLE I 7.7 (6) 6.0 (5)
RIFLE F 5.1 (4) 4.8 (4)
Death in 90 days 24.4 (19) 23.8 (20) 1.0
Death or Dialysis in 30 days 23.1 (18) 22.6 (19) 1.0
Abbreviations: AKI, acute kidney injury; AKIN, acute kidney injury network; EPO, erythropoietin-b; ICU, intensive care unit; RAVC, Relative Average Value of Creatinine; UO,
urine output.
Results are mean±s.d., median (interquartile range), or % (n). Numbers are shown in square brackets where these differ from the initial cohort.
aAKIN-creatinine and percentage increase definitions include the first plasma creatinine measurement beyond 48 h (mean 57±13 h).
bAKI AKIN-Total: The sum of AKI AKIN-creatinine, AKI AKIN-UO, and dialysis in 7 days.
cAKI RIFLE-creatinine: At least a 50% rise from baseline sustained for at least 24 h within 7 days of randomization.
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Table A2 | Intervention trial efficacy of erythropoietin for the subgroup not AKI on randomization
Placebo EPO P
(a) Continuous (non-categorical) variables
Primary outcome
ITT population (n=47) (n=61)
RAVC 4.6±18 8.5±27 0.004
3.4 (17 to 9.3) 4.9 (4.6 to 17) 0.008
Secondary outcomes
Length of ICU Stay (h) 88 (42–181) 84 (46–132) 0.81
Length of hospital stay (days) 17 (8–39) 17 (12–39) 0.94
(b) Categorical variables % (n)
AKI in 7days 14.9 (7) 29.5 (18) 0.11
AKI AKIN-creatininea 12.8 (6) 24.6 (15) 0.15
AKI AKIN-UOa 44.7 (21) 68.9 (42) 0.018
AKI AKIN-Totalb 48.9 (23) 70.5 (43) 0.029
AKI RIFLE-creatininec 0.0 (0) 13.1 (8) 0.0093
Dialysis in 30 days 4.3 (2) 1.6 (1) 1.0
Death in 7 days 17.0 (8) 11.5 (7) 0.42
Death in 30 days 21.3 (10) 23.0 (14) 1.0
Abbreviations: AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; EPO, erythropoietin-b; ICU, intensive care unit; ITT, Intention-To-Treat; RAVC, relative average value
of creatinine; UO, urine output.
Results are mean±s.d., median (interquartile range), or % (n).
aAKIN-creatinine and percentage increase definitions include the first plasma creatinine measurement beyond 48 h (mean 57±13 h).
bAKI AKIN-Total: The sum of AKI AKIN-creatinine, AKI AKIN-UO, and dialysis in 7 days. AKI in 7 days: At least a 50% rise or 0.3-mg/dl (26.4-mmol/l) rise from baseline or dialysis
within 7 days of randomization.
cAKI RIFLE-creatinine: At least a 50% rise from baseline sustained for at least 24 h within 7 days of randomization.
Table A3 | Intervention trial 30 day safety analysis: serious adverse events (SAEs) according to Body System (ITT, n=162)
Placebo EPO
SAEs
CTCAE grade CTCAE grade
body system SAE (n) Patients (n) 3 4 5 SAE (n) Patients (n) 3 4 5
3. Blood/bone marrow 13 12 13 23 18 21 2
4. Cardiac arrhythmias 12 12 7 5 5 5 4 1
5. Cardiac general 10 8 6 2 2 9 9 4 3 2
6. Coagulation 1 1 1
8. Death (other) 7 7 7 9 9 9
9. Dermatology/skin 3 3 2 1
11. Gastrointestinal 4 4 1 3 9 8 6 3
13. Hemorrhage/bleeding 1 1 1
15. Infection 13 12 12 1 26 21 23 3
17. Metabolic/laboratory 11 8 11 32a 25 27 5
18. Musculoskeletal 1 1 1
19. Neurology 19 17 12 3 4 13 12 11 2
21. Pain 3 3 3 1 1 1
22. Pulmonary/upper respiratory 12 11 5 4 3 16 14 7 6 3
23. Renal/genitourinary 3 3 1 2 2 2 1 1
27. Syndromes 1 1 1
28. Vascular 5 5 4 1 5 5 3 1 1
Total 115 105 78 20 17 154 133 111 27 16
No SAEs 21 23
EPO specific SAEs
DVT 5 5 4 1 2 2 2
SVT 3 3 2 1
Pulmonary embolism 1 1 1 1 1 1
Thromboembolism 1 1 1
Ischemic 2 2 1 1
Hypertension 2 2 2 2 2 2
Stroke 3 3 2 1 1 1 1
Seizure 4 4 1 2 1 1 1 1
Cardiac failure 1 1 1
Myocardial infarction 3 3 1 2
Allergic response
VF arrest 3 3 3
Atrial fibrillation 6 6 5 1 3 3 3
Total 30 30 17 11 2 14 14 10 2 2
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; EPO, erythropoietin-b.
aP=0.003. Although more frequent in the EPO group, metabolic disturbances were similar in both the groups except for acidosis and alkalosis: all shown as respective placebo
and EPO pairings: acidosis: 0, 5; alkalosis: 1, 6; abnormal liver function tests: 0, 1; elevated alkaline phosphatase: 1, 0; elevated ALT: 0, 1; elevated AST: 1, 2; hyperglycemia: 0, 2;
hyperkalemia: 2, 1; hypernatremia: 0, 2; hypoalbuminemia-intermittent: 0, 1; hypokalemia: 3, 5; hyponatremia: 2, 2; hypophosphatemia: 1, 4.
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